Table 1 Baseline characteristics of the participants
Characteristic | ITT (n = 60) | ESA (n = 57) |
|---|---|---|
Median Age (range), years | 62 (35–72) | 62 (35–72) |
≥60 years | 35 (58.3%) | 35(59.6%) |
Sex (male) | 26 (43.3%) | 25(43.9%) |
Clinical stage | Â | Â |
IIIB | 1 (1.7%) | 1(1.8%) |
IIIC | 1 (1.7%) | 1(1.8%) |
IV | 58 (96.7%) | 55(96.5%) |
Smoking history | Â | Â |
Ever | 11 (18.3%) | 11(19.3%) |
Current | 9 (15.0%) | 7(12.3%) |
Never | 40 (66.7%) | 39(68.4%) |
ECOG PS | Â | Â |
0 | 22 (36.7%) | 22(38.6%) |
1 | 37 (61.7%) | 34(59.6%) |
2 | 1 (1.7%) | 1(1.8%) |
Recurrent NSCLC | 2 (3.3%) | 2(3.5%) |
Brain metastases | 21 (35.0%) | 21(36.8%) |
EGFR mutations | Â | Â |
19del | 30 (50.0%) | 30(52.6%) |
L858R | 30 (50.0%) | 27(47.4%) |
Concurrent mutations | 31 (51.7%) | 30(52.6%) |
Pathogenic concurrent mutations | 29 (48.3%) | 28(49.1%) |